CASIF — CASI PHARMACEUTICALS, INC.
CIK 1962738 · SEC EDGAR fundamentals
Headline figures
Top-line sales for the most-recent fiscal year
FY2025 · 20-F
Profit after all expenses, taxes, interest
FY2025 · 20-F
Net income per diluted share outstanding
FY2025 · 20-F
Cash actually generated by the business
FY2025 · 20-F
Balance sheet
Everything the company owns
FY2025 · 20-F
Everything the company owes
FY2025 · 20-F
Assets minus liabilities (book value)
FY2025 · 20-F
Debt due more than 12 months out
FY2024 · 20-F
Revenue history
Revenues · FY values from Revenues
| Fiscal year | Revenue | vs prior | Source |
|---|---|---|---|
| FY2025 | $33.9M | -21.4% | 20-F |
| FY2024 | $43.1M | +42.9% | 20-F |
| FY2023 | $30.2M | +99.2% | 20-F |
| FY2022 | $15.1M | — | 20-F |
Data sources & methodology
- SEC EDGAR — official company filings (full-text search) ↗
- SEC EDGAR — institutional Form 13F holdings ↗
- U.S. House Clerk — Periodic Transaction Reports (Congress) ↗
All figures derive from official, public-domain government filings. Read our methodology for how we collect, process and score this data. See the methodology →
TZ Researched & published by TradesZ Research
Not investment advice. Figures sourced from the SEC's XBRL CompanyFacts API — public-domain federal records. Companies occasionally restate prior-year numbers; we show the latest filed value per fiscal year.